Neutropenia – Market outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2020 To 2030
Neutropenia is defined as an absolute neutrophil count (ANC) of less than 1500 per microliter (1500/microL). Severe neutropenia is defined as less than 500 per microliter (500/microL).
Epidemiology-
The causes of primary defects of
neutrophil function include failure of the following: Adhere to endothelial
cells, Migrate into inflammation sites (abnormal chemotaxis), Ingest and kill
bacteria, Produce microbicidal compounds to kill fungi and other pathogens,
Form phagolysosomes, Make high concentrations of toxic reactive oxygen species.
Low levels of neutrophils may be due to
hypoplastic bone marrow, an infection, radiation exposure, tumour infiltration
of the bone marrow, myelofibrosis, prolonged exposure to a drug, or a
hereditary disorder. Congenital neutropenia or Kostmann syndrome is acquired in
an autosomal recessive fashion.
Drugs are known to cause neutropenia to
include: Quinidine Aminopyrine, Cephalosporin, Sulfonamides, Hydralazine,
Penicillins, Heavy metals, Phenothiazine.
Epidemiology-
Hsieh and collaborators reported that in
the United States, the prevalence of neutropenia was 0.38% among
Mexican-Americans, 0.79% among whites, and 4.5% among black participants.
The competitive
landscape of Neutropenia includes country-specific approved as well as pipeline
therapies. Any asset/product-specific designation or review and Accelerated
Approval are being tracked and supplemented with analyst commentary.
KOLs insights of Neutropenia
across 8 MM market from the centre of Excellence/ Public/ Private hospitals
participated in the study. Insights around current treatment landscape,
epidemiology, clinical characteristics, future treatment paradigm, and Unmet
needs.
Neutropenia
Market Forecast:
Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data
Inputs with sourcing, Market Event, and Product Event, Country specific
Forecast Model, Market uptake and patient share uptake, Attribute Analysis,
Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
S. No Asset Company Stage
1 Mavorixafor X4
Pharmaceuticals Phase 1
2 HSP-130 Hospira,
now a wholly-owned subsidiary of Pfizer Phase
1
3 EC-18 Enzychem
Lifesciences Corporation Phase 2
4 Eflapegrastim Spectrum
Pharmaceuticals, Inc Phase 1
5 pegfilgrastim Kyowa
Kirin Co., Ltd. Phase 2
6 rHSA-GCSF 2.4mg Tianjin
SinoBiotech Ltd. Phase 2
7 Myelo001 Myelo
Therapeutics GmbH Phase 2
8 Lozanoc Mayne
Pharma International Pty Ltd Phase 2
9 Pegfilgrastim Eurofarma
Laboratorios S.A. Phase 1
10 TXA127 Tarix
Pharmaceuticals Phase 2
Comments
Post a Comment